Iterum Therapeutics plc
ITRM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $1 | $0 | $0 |
| Gross Profit | $0 | -$1 | -$0 | $0 |
| % Margin | 94.9% | – | – | – |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $4 | $3 | $2 |
| SG&A Expenses | $6 | $4 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8 | $5 | $3 | $4 |
| Operating Income | -$7 | -$6 | -$4 | -$4 |
| % Margin | -1,892.8% | – | – | – |
| Other Income/Exp. Net | -$1 | -$1 | -$1 | -$3 |
| Pre-Tax Income | -$9 | -$6 | -$5 | -$7 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$7 | -$5 | -$7 |
| % Margin | -2,302.3% | – | – | – |
| EPS | -0.2 | -0.16 | -0.14 | -0.25 |
| % Growth | -25% | -14.3% | 44% | – |
| EPS Diluted | -0.2 | -0.16 | -0.14 | -0.25 |
| Weighted Avg Shares Out | 46 | 40 | 34 | 20 |
| Weighted Avg Shares Out Dil | 46 | 40 | 34 | 20 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$8 | -$6 | -$4 | -$5 |
| % Margin | -2,064.4% | – | – | – |